%PDF-1.4
%
89 0 obj
<>
endobj
86 0 obj
<>
endobj
159 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-05-11T16:19:10Z
2024-03-28T16:39:18-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:39:18-07:00
application/pdf
Heather
2002-998.june
uuid:fab80674-1dd1-11b2-0a00-cd08275d6100
uuid:fab80677-1dd1-11b2-0a00-aa0000000000
endstream
endobj
75 0 obj
<>
endobj
76 0 obj
<>
endobj
90 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 59 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 61 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 63 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 65 0 R/Type/Page>>
endobj
35 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 67 0 R/Type/Page>>
endobj
48 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 69 0 R/Type/Page>>
endobj
181 0 obj
[185 0 R]
endobj
182 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6303 0.7762 -0.7762 0.6303 16.7778 46.0632 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.1981 Tw 10 0 0 10 54 713.1616 Tm
[(questions because of the dif)17.7 (ficulties of obtaining healthy)]TJ
0.02499 Tw 0 -1.2 TD
(synovial samples and assessing the severity of OA.)Tj
0.0621 Tw 1.2 -1.2 Td
[(W)79.9 (e speculate that )17.7 (TTP)-275.4 (production is induced in patients)]TJ
0.07381 Tw -1.2 -1.2 Td
[(with RA)-269 (as a negative feedback of )17.7 (TNF-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 17.6412 0 Td
(overproduction,)Tj
0.0806 Tw -17.6411 -1.2 Td
[(and that )17.7 (TTP)-293.9 (may af)17.7 (fect the course of RA)-275.9 (by reducing the)]TJ
0.0388 Tw T*
[(production of )17.8 (TNF-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.0388 Tw 8.8658 0 Td
(in the synovium. Our current hypoth-)Tj
0.05611 Tw -8.8658 -1.2 Td
[(esis is that compounds that mimic the properties of )17.7 (TTP)-269.4 (or)]TJ
0.01961 Tw T*
[(that enhance )17.7 (TTP)-232.8 (gene expression, or even )17.7 (TTP)-232.8 (gene thera-)]TJ
0.0502 Tw T*
(pies, may serve as a tool for controlling joint inflammation)Tj
0.02499 Tw T*
(and destruction in severe RA.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 54 571.1616 Tm
[(W)79.9 (e thank Hiromi )36.8 (Y)110.8 (uhashi for excellent technical assistance.)]TJ
/T1_3 1 Tf
0 Tw 10 0 0 10 54 547.1616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 537.1616 Tm
[(1.)-875.1 (Saxne )17.7 (T)74 (, Palladino MA)-220.2 (Jr)39.7 (, Heinegard D, )17.7 (T)69.9 (alal N, )17.7 (W)79.9 (ollheim F)73.9 (A.)]TJ
1.675 -1.25 Td
(Detection of tumor necrosis factor alpha but not tumor necrosis)Tj
0 -1.25 TD
(factor beta in rheumatoid arthritis synovial fluid and serum.)Tj
T*
(Arthritis Rheum 1988;31:1041-5.)Tj
-1.675 -1.25 Td
[(2.)-875.1 (Hopkins SJ, Meager )54.8 (A. Cytokines in synovial fluid: II. )17.7 (The )]TJ
1.675 -1.25 Td
(presence of tumour necrosis factor and interferon. Clin Exp)Tj
T*
(Immunol 1988;73:88-92.)Tj
-1.675 -1.25 Td
[(3.)-875.1 (T)69.9 (etta C, Camussi G, Modena )17.7 (V)128.9 (, Di )17.7 (V)59.8 (ittorio C, Baglioni C. )17.7 (T)35 (umour)]TJ
1.675 -1.25 Td
(necrosis factor in serum and synovial fluid of patients with active)Tj
T*
[(and severe rheumatoid arthritis. )54.8 (Ann Rheum Dis 1990;49:665-7.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Kef)17.7 (fer J, Probert L, Cazlaris H, et al. )17.7 (T)35 (ransgenic mice expressing)]TJ
1.675 -1.25 Td
(human tumour necrosis factor: a predictive genetic model of)Tj
T*
(arthritis. EMBO J 1991;10:4025-31.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Liang P)110.7 (, Pardee )54.8 (AB. Dif)17.7 (ferential display of eukaryotic messenger)]TJ
1.675 -1.25 Td
[(RNA)-220.2 (by means of the polymerase chain reaction. Science)]TJ
0 Tc 0 Tw T*
(1992;257:967-71.)Tj
-0.00011 Tc 0.02499 Tw 31.325 40.921 Td
[(6.)-875.1 (Ali M, Markham )54.8 (AF)79.7 (, Isaacs JD. )54.8 (Application of dif)17.7 (ferential display)]TJ
1.675 -1.25 Td
(to immunological research. J Immunol Methods 2001;250:29-43.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Blackshear PJ. )17.7 (T)35 (ristetraprolin and other CCCH tandem zinc-finger)]TJ
1.675 -1.25 Td
[(proteins in the regulation of mRNA)-220.2 (turnover)54.8 (. Biochem Soc )17.7 (T)35 (rans)]TJ
0 Tc 0 Tw T*
(2002;30:945-52.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(8.)-875.1 (Carballo E, Lai )17.7 (WS, Blackshear PJ. Feedback inhibition of)]TJ
1.675 -1.25 Td
[(macrophage tumor necrosis factor)19.7 (-alpha production by )]TJ
T*
(tristetraprolin. Science 1998;281:1001-5.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.675 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Heximer SP)110.7 (, Forsdyke DR. )54.8 (A)-220.1 (human putative lymphocyte G0/G1)]TJ
2.175 -1.25 Td
(switch gene homologous to a rodent gene encoding a zinc-binding)Tj
T*
[(potential transcription factor)54.8 (. DNA)-220.2 (Cell Biol 1993;12:73-88.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Lai )17.7 (WS, Carballo E, Strum JR, Kennington EA, Phillips RS,)]TJ
2.1381 -1.25 Td
[(Blackshear PJ. Evidence that tristetraprolin binds to )54.8 (AU-rich)]TJ
T*
(elements and promotes the deadenylation and destabilization of)Tj
T*
(tumor necrosis factor alpha mRNA. Mol Cell Biol )Tj
0 Tc 0 Tw T*
[(1999;19:431)36.9 (1-23.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(12.)-875.1 (T)69.9 (aylor GA, Carballo E, Lee DM, et al. )54.8 (A)-220.1 (pathogenetic role for )17.7 (TNF)]TJ
2.175 -1.25 Td
(alpha in the syndrome of cachexia, arthritis, and autoimmunity)Tj
T*
[(resulting from tristetraprolin \(TTP\) deficiency)64.8 (. Immunity)]TJ
0 Tc 0 Tw T*
(1996;4:445-54.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Raghavan )54.8 (A, Robison RL, McNabb J, Miller CR, )17.7 (W)39.8 (illiams DA,)]TJ
2.175 -1.25 Td
[(Bohjanen PR. HuA)-220.2 (and tristetraprolin are induced following )17.7 (T)-257.1 (cell)]TJ
T*
(activation and display distinct but overlapping RNA-binding )Tj
T*
(specificities. J Biol Chem 2001;276:47958-65.)Tj
-2.175 -1.25 Td
[(14.)-875.1 (Brooks SA, Connolly JE, Diegel RJ, Fava RA, Rigby )17.7 (WFC.)]TJ
2.175 -1.25 Td
(Analysis of the function, expression, and subcellular distribution of)Tj
T*
[(human tristetraprolin. )54.8 (Arthritis Rheum 2002;46:1362-70.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Moos )17.7 (V)128.9 (, Fickert S, Muller B, )17.7 (W)79.9 (eber U, Sieper J.)]TJ
2.175 -1.25 Td
(Immunohistological analysis of cytokine expression in human)Tj
T*
(osteoarthritic and healthy cartilage. J Rheumatol 1999;26:870-9.)Tj
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_4 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(T)91.8 (sutsumi, et al: TTP)-257.3 (in RA)]TJ
0 Tc 0 Tw 60.9375 -0.0313 Td
(1049)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_5 8 Tf
120.98 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_6 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
69 0 obj
<>stream
8;Z\7>EZlH%.jENW9`edJn:'0J1UZOWASCE1r`XH[Ql&,Y@*Am#q1AbrU0i9I4X-a
>&&r9H*]lLhX\g0\04='EAd'u0KIb1MbK&S)-+33g4sCUNtb5,iPrI<:4b8A;ZdGC&&/U4d?%,^r8b%`iUm_Va\"Ug4eLQ'+EfIe2#tOGDA&rB"#n[5TDCf)t7\;_O(YA&FVIXAd156Cm$<:rQ~>
endstream
endobj
73 0 obj
[/Indexed/DeviceRGB 255 72 0 R]
endobj
72 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
146 0 obj
<>
endobj
97 0 obj
<>
endobj
101 0 obj
<>
endobj
51 0 obj
<>
endobj
92 0 obj
<>
endobj
133 0 obj
<>
endobj
164 0 obj
<>
endobj
93 0 obj
<>
endobj
128 0 obj
<>stream
HU{PSgM.#yInY|Z:
.EP @ (/ @
_Xl}Ti}vGڵˌnggΙ7|3wf߇cN1QQDblJyJhG/4'֟`:?ML9gxά牖"O;KUկ04
#qjl?p48x^PpprIB*Jϐ3(w O
\(1+Ki\0ᙙ;
eBi#nbF$cR4%M(Nb$;QD2+)#rd2Q(E*~c#Ip,p"6bw,
#0[b;1=
NSabxӹrWaʗwL